Luminex Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Luminex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNX, but not buy additional shares or sell existing shares.
View analyst ratings for Luminex or view top-rated stocks.

Wall Street analysts have given Luminex a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Luminex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Luminex saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,380,000 shares, a drop of 22.2% from the March 31st total of 3,060,000 shares. Based on an average trading volume of 1,140,000 shares, the days-to-cover ratio is presently 2.1 days. Approximately 5.4% of the company's stock are sold short.
View Luminex's Short Interest.

Luminex is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings data on Sunday, February, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.13 by $0.12. The medical instruments supplier earned $111.39 million during the quarter, compared to analysts' expectations of $104.57 million. Luminex had a net margin of 4.60% and a trailing twelve-month return on equity of 3.75%. The firm's quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 earnings per share.
View Luminex's earnings history.

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has increased by 36.0% and is now trading at $36.86.
View which stocks have been most impacted by COVID-19.

Luminex declared a quarterly dividend on Tuesday, February 9th. Shareholders of record on Thursday, March 25th will be paid a dividend of $0.10 per share on Thursday, April 15th. This represents a $0.40 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Wednesday, March 24th.
View Luminex's dividend history.

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.09%.
View Luminex's dividend history.

3 brokerages have issued 1-year price targets for Luminex's shares. Their forecasts range from $37.00 to $37.00. On average, they expect Luminex's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Luminex or view top-rated stocks among Wall Street analysts.

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bio-Techne (TECH), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of LMNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology Group (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.54%), Copeland Capital Management LLC (3.03%), Cowen Prime Services LLC (0.38%), Envestnet Asset Management Inc. (0.35%), Rhumbline Advisers (0.28%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.27%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., State of New Jersey Common Pension Fund D, Dupont Capital Management Corp, Quantitative Systematic Strategies LLC, State of Alaska Department of Revenue, Strs Ohio, Fisher Asset Management LLC, and Texas Permanent School Fund. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex or view top insider-selling stocks.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Copeland Capital Management LLC, BCK Capital Management LP, Envestnet Asset Management Inc., Migdal Insurance & Financial Holdings Ltd., Juncture Wealth Strategies LLC, and Exchange Traded Concepts LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex or or view top insider-buying stocks.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LMNX stock can currently be purchased for approximately $36.86.

Luminex has a market capitalization of $1.74 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

Luminex employs 1,325 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]